ReviewActa obstetricia et gynecologica Scandinavica2026
Chemotherapy resistance and risk stratification in gestational trophoblastic neoplasia: A systematic review and network meta-analysis.
Review in Acta obstetricia et gynecologica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionGestational trophoblastic neoplasia (GTN) is highly chemosensitive, but resistance to initial chemotherapy remains clinically important despite International Federation of Gynecology and Obstetrics (FIGO) score-guided management. Evidence on pretreatment predictors of chemoresistance and comparative chemoresistance across chemotherapy regimens remains limited. This study aimed to estimate the burden of chemoresistance, identify pretreatment risk factors, and compare chemotherapy regimens using pairwise and network meta-analysis to inform risk stratification and future treatment optimization. MATERIAL AND
methodsEight databases (PubMed, Embase, Cochrane Library, Web of Science, CBM, CNKI, VIP, and Wanfang) were searched from inception to August 26, 2025. Two reviewers independently screened records, extracted data, and assessed risk of bias using the RTI Item Bank. Pairwise meta-analyses were used to pool the chemoresistance rate and evaluate associations between pretreatment factors and chemoresistance. A frequentist random-effects network meta-analysis was performed to compare chemoresistance risks across chemotherapy regimens, with ranking probabilities summarized using the surface under the cumulative ranking curve (SUCRA).
resultsFifty-three studies involving 7585 patients and 1997 resistant cases yielded a pooled chemoresistance rate of 23.8% (95% CI: 20.7%-27.1%; p < 0.001). Higher chemoresistance was associated with choriocarcinoma, antecedent full-term pregnancy, a high FIGO score, higher pretreatment β-hCG, especially > 10
conclusionsApproximately one quarter of patients with GTN develop chemoresistance. Pretreatment factors, including clinicopathologic type when available, tumor burden, FIGO score and stage, antecedent pregnancy characteristics, and pretreatment β-hCG level, may help identify patients at higher risk of chemoresistance. Exploratory regimen-ranking analyses suggested lower predicted chemoresistance for etoposide-containing regimens, particularly FAEV; however, these findings require prospective validation before they can inform treatment selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.